Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11591546 | 0.93 | HSD17B10 (0.33) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL4838782 | 0.93 | HSD17B10 (0.33) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL8528940 | 0.93 | HSD17B10 (0.33) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL9809110 | 0.93 | HSD17B10 (0.33) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL27892742 | 0.91 | HTT (0.52) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL27905256 | 0.91 | HTT (0.52) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL8586102 | 0.91 | HTT (0.52) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL28602530 | 0.88 | HTT (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL29083539 | 0.88 | HTT (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL30549095 | 0.88 | HTT (0.56) | HTTMEN1THRBKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180147202-A1 | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180147202-A1 | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147202-A1 | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE | TBK1, TBKBP1, TNKS | HTT 1752/4885MEN1 3985/4885THRB 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.